Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB4211
    • CB5138 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 27, 2018 9:00am EDT

CohBar Added to Russell 2000® Index

Jun 25, 2018 12:08pm EDT

CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions

Jun 07, 2018 8:59am EDT

CohBar Announces the Appointment of Dr. Philippe Calais to its Board

Jun 06, 2018 9:45am EDT

CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018

May 29, 2018 9:00am EDT

CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions

May 15, 2018 4:03pm EDT

CohBar, Inc. Announces First Quarter 2018 Financial Results

Apr 18, 2018 4:05pm EDT

CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange

Apr 13, 2018 4:05pm EDT

CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000

Apr 02, 2018 4:03pm EDT

CohBar, Inc. Announces Fourth Quarter 2017 Financial Results

Mar 29, 2018 4:10pm EDT

CohBar, Inc. Announces Closing of First Tranche of Private Placement

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Next Pagearrow_forward
  • Email Alerts
  • Tear Sheet
  • Contacts
©2023 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use